Bifogade filer
Change of distribution partner in Portugal
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that it has changed its commercial partner in Portugal. Werfen, an IVD Global leader already distributing IndiTreat® in Spain, takes over the activities in the Portuguese market from Lab52. With this expanded partnership agreement, Werfen will leverage the synergies between their two companies, Werfen España and Werfen Portugal.
2cureX today announced today the extension of the IndiTreat® distribution agreement with Werfen. Under the terms of this extension, Werfen’s distribution territory now includes Spain, Portugal and Andorra. The agreement with the previous distributor, Lab52, has been terminated.
With a population of more than 10 million people and 10,500 new colorectal cancer patients every year, Portugal is a very important market for 2cureX. Its public healthcare system (Serviço Nacional de Saúde, SNS) is organized in eight health regions and has approximately 40 hospitals.
Strengthening the relationship with Werfen
“We are very excited to now also have Werfen as our partner in Portugal and that we have further strengthened our relationship,” says Fernando Andreu, CEO of 2cureX. “Werfen is a global leader in diagnostics, and because of their origin and history they are in an excellent position to leverage the synergies between two very close countries like Spain and Portugal.”
The best distributor for Portugal
“This is fantastic news,” says Jesper Floyd Kristiansen, VP Business Development at 2cureX. “Over the last twelve months, the Werfen team has demonstrated its strong commitment and dedication to IndiTreat® in Spain. We now have the best distributor in Portugal to bring the benefits of IndiTreat® to the Portuguese patients and healthcare professionals.”
The agreement with Werfen was signed in September 2021 for an initial term of three years. Other terms of the agreement have not been disclosed. Sales impact of this extension is expected to show in 2023.
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com